ABL Bio Inc. (KOSDAQ:298380)

South Korea · Delayed Price · Currency is KRW

157,700

+2,100 (1.35%)

Apr 10, 2026, 3:30 PM KST

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Biotechnology (Startups)	79.35B	33.40B	65.55B	67.30B	5.33B
Biotechnology (Startups) Growth	137.55%	-49.04%	-2.61%	1162.19%	-
Total	79.35B	33.40B	65.55B	67.30B	5.33B
Total Growth	137.55%	-49.04%	-2.61%	1162.19%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
South Korea	400.00M	300.00M	2.00B	2.38B	483.55M
South Korea Growth	33.33%	-84.97%	-16.30%	393.11%	-
United States	5.77B	33.10B	63.55B	62.32B	4.85B
United States Growth	-82.56%	-47.91%	1.98%	1185.24%	-
UK	73.18B	-	-	-	-
China	-	-	-	2.60B	-
Total	79.35B	33.40B	65.55B	67.30B	5.33B
Total Growth	137.55%	-49.04%	-2.61%	1162.19%	-

Source: S&P Global Market Intelligence.